Maria del Rosario Aschero
Investigador post-doc
Research group
Rosario Aschero graduated with a degree in Biotechnology in 2015 from the Universidad Argentina de la Empresa (UADE) in Buenos Aires.
In 2015 she obtained a scholarship from the ANPCyT (Agencia Nacional de Promoción Científica y Tecnológica) and in 2018, a scholarship from CONICET (National Council of Science and Technology) to carry out her doctoral studies in metastatic retinoblastoma. In 2021 she obtained the title of Doctor of Medical Sciences awarded by the University of Buenos Aires.
Currently, she is a postdoctoral researcher in the Pediatric Cancer Treatment research group at the Institut de Recerca Sant Joan de Déu.
Professional network profiles
Last Publications
- Aschero MR, Ganiewich D, Lamas G, Restrepo-Perdomo CA, Ottaviani D, Zugbi S, Camarero S, Néspoli E, Cuadrado-Vilanova M, Pérez-Jaume S, Pascual-Pastó G, Sampor C, Grigorovski N, Salas B, Suñol M, Carcaboso AM, Mora J, de Dávila MTG, Doz F, Radvanyi F, Abramson DH, Llera AS, Schaiquevich PS, Lubieniecki F and Chantada G Immunohistochemical expression of TFF1 is a marker of poor prognosis in retinoblastoma. PEDIATRIC BLOOD & CANCER . 71(1): .
- Aschero MR, Castillo H, Baulenas-Farrés M, Resa-Parés C, Jiménez-Cabaco A, Rodriguez E, Monterrubio C, Pérez-Jaume S, Suñol M, Chantada G, Lavarino C, Mora J and Carcaboso AM Prognostic value of xenograft engraftment in patients with metastatic high-risk neuroblastoma PEDIATRIC BLOOD & CANCER . 70(6): .
- Pascual-Pastó G, Resa-Parés C, Castillo H, Aschero MR, Baulenas-Farrés M, Vilà-Ubach M, Burgeño-Sandoval V, Balaguer-Lluna L, Cuadrado-Vilanova M, Gene-Olaciregui N, Martinez N, Pérez-Jaume S, de Alava, E, Tirado, OM, Lavarino C, Mora J and Carcaboso AM Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma BIOCHEMICAL PHARMACOLOGY . 208: 115408-115408.
Projects
- Project name:
- SGR 2022-2024_Grup de recerca en tumors del desenvolupament
- Leader
- Jaume Mora Graupera
- Funding entities:
- Agaur - Agència de Gestió d'Ajuts Universitaris i de Recerca
- Code
- 2021 SGR 01612
- Starting - finishing date:
- 2022 - 2024
- Project name:
- Inhibition of the PI3K/Akt pathway in pediatric high grade and diffuse intrinsic pontine gliomas (pHGG/DIPG)
- Leader
- Angel Montero Carcaboso
- Funding entities:
- Fundació La Marató de TV3
- Code
- 201927-30
- Starting - finishing date:
- 2020 - 2023
- Project name:
- "Origen fetal" de la diabetes del adulto: Fallo de la célula-beta mediado por alteraciones epigenéticas
- Leader
- José Carlos Jiménez Chillarón
- Funding entities:
- Fundación Salud 2000 (Merck Salud)
- Code
- 2009097
- Starting - finishing date:
- 2008 - 2010
News
-
Researchers at IRSJD develop a method to predict the efficacy of a potent nanomedicine in a severe childhood cancer
Researchers at IRSJD have developed a method that predicts the anticancer efficacy of nab-paclitaxel, a well-known nanomedicine, in mouse models, for treatment of Ewing sarcoma, a severe cancer affecting the bones and soft tissue of children and adolescents.